Francesca Lombardi1, Rosalba Ricci2, Simone Belmonti3, Massimiliano Fabbiani4, Alberto Borghetti1, Gianmaria Baldin5, Arturo Ciccullo6, Enrica Tamburrini1,3, Elena Visconti1, Maurizio Sanguinetti2, Simona Di Giambenedetto1,3. 1. UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. 2. Institute of Microbiology and Virology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. 3. Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. 4. Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy. 5. Mater Olbia Hospital, 07026 OIbia, Italy. 6. Gemelli, Molise Hospital, 86100 Campobasso, Italy.
Abstract
BACKGROUND: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March-June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37-1.42). CONCLUSION: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.
BACKGROUND: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March-June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37-1.42). CONCLUSION: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.
Authors: James M Tesoriero; Carol-Ann E Swain; Jennifer L Pierce; Lucila Zamboni; Meng Wu; David R Holtgrave; Charles J Gonzalez; Tomoko Udo; Johanne E Morne; Rachel Hart-Malloy; Deepa T Rajulu; Shu-Yin John Leung; Eli S Rosenberg Journal: JAMA Netw Open Date: 2021-02-01
Authors: Roger Chou; Tracy Dana; David I Buckley; Shelley Selph; Rongwei Fu; Annette M Totten Journal: Ann Intern Med Date: 2020-05-05 Impact factor: 51.598